Daily Stock Analysis, CNDT, CONCERT PHARMACEUTICALS INC, priceseries

CONCERT PHARMACEUTICALS INC. Daily Stock Analysis
Stock Information
Open
6.90
Close
6.65
High
6.98
Low
6.58
Previous Close
6.98
Daily Price Gain
-0.33
YTD High
15.48
YTD High Date
Feb 21, 2019
YTD Low
5.26
YTD Low Date
Aug 9, 2019
YTD Price Change
-4.10
YTD Gain
-38.14%
52 Week High
23.39
52 Week High Date
Sep 7, 2018
52 Week Low
5.26
52 Week Low Date
Aug 9, 2019
52 Week Price Change
-15.01
52 Week Gain
-69.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 21. 2018
17.86
Mar 22. 2018
19.63
21 Trading Days
9.93%
Link
LONG
Aug 2. 2018
18.64
Sep 18. 2018
22.68
32 Trading Days
21.66%
Link
LONG
Jan 4. 2019
10.99
Feb 28. 2019
14.64
37 Trading Days
33.21%
Link
Company Information
Stock Symbol
CNDT
Exchange
NASDAQ
Company URL
http://www.concertpharma.com
Company Phone
781-860-0045
CEO
Roger D. Tung
Headquarters
Massachusetts
Business Address
99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001367920
About

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs for renal disease, CNS disorders, inflammation and hematologic disorders. It also creates novel medicines that address commercially important needs by applying its deuterated chemical entity platform to compounds with well-characterized pharmacological activity. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.